Please login to the form below

Not currently logged in
Email:
Password:

No cardiovascular risk found in Prilosec/ Nexium says FDA

The FDA's review of clinical studies involving AstraZeneca's antacid drugs Nexium and Prilosec does not demonstrate an increase in heart attacks and sudden death

The FDA's review of clinical studies involving UK-headquartered AstraZeneca's (AZ) antacid drug Nexium (esomeprazole) and Prilosec (omeprazole) has not demonstrated an increase in heart attacks and sudden death.

Since May 2007, the FDA has been conducting a safety review of the drugs, which are approved to treat gastroesophageal reflux disease, when AZ submitted the results of two small, long-term studies that suggested the drug could increase the risk of heart problems and sudden death. Prilosec is also marketed in OTC versions in the US.

The FDA asked AZ to submit extra data about the drugs for review. The agency said its review of the two long-term studies, along with 14 additional studies, shows the products are "not likely to be associated with an increased risk of heart problems".

11th December 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics